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The simplification of current vaccine administration regimes is of crucial interest in order to further sustain
and expand the high impact of vaccines for public health. Most vaccines including the vaccine against
hepatitis B need several doses to achieve protective immunization. In order to reduce the amount of
repetitive injections, depot-based approaches represent a promising strategy. We present the application of
novobiocin-sensitive biohybrid hydrogels as a depot for the pharmacologically controlled release of a
vaccine against hepatitis B. Upon subcutaneous implantation of the vaccine depot intomice, we were able to
release the vaccine by the oral administration of the stimulus molecule novobiocin resulting in successful
immunization of the mice. This material-based vaccination regime holds high promises to replace classical
vaccine injections conducted bymedical personnel by the simple oral uptake of the stimulus thereby solving
a major obstacle in increasing hepatitis B vaccination coverage.
R
outine vaccination is one of themost effective means to increase global health with the power to completely
eliminate infectious diseases such as smallpox1 and polio2. In order to increase worldwide immunization,
vaccines are actively promoted by large vaccination campaigns such as theGlobal Alliance for Vaccines and
Immunization (GAVI)3 having prevented 5.4 million future deaths in 10 years4. However, these campaigns are
accompanied with huge financial (US$ 4.5 billion in 10 years for GAVI), organizational and logistic efforts due to
the fact that repeated vaccine injections associated with several medical consultations are needed. As the density
of health workers is a major obstacle to achieve sufficient vaccination coverage5, novel vaccine development and
delivery technologies reducing professional medical care are estimated to have amajor future impact on health in
developing countries6. This is especially a problem in the case of hepatitis B virus (HBV) infections with 600,000
deaths per year7 although the worldwide coverage with the respective vaccine is estimated at 75%8. One promising
strategy to reduce medical consultations associated with the prime-boost vaccination regime would be the
replacement of repeated injections by the release of the vaccine from a body depot. As the prime and boost
vaccine doses need to be released to the body in a pulse-like profile in order to induce long-lasting immune
protection, stimulus-sensitive materials9 would be well suited to act as such a depot as they would allow for the
development of a release profile similar to the conventional vaccine delivery.
With the development of biohybrid materials being responsive to clinically approved small molecules at
pharmacologically feasible concentrations10–14, a promising direction towards a safe and patient-compliant bio-
medical use of stimulus-inducible hydrogels was discussed. To this aim, branched polymers were functionalized
with protein domains such as the gyrase B (GyrB) thereby allowing for the coumermycin-inducible dimerization
of the GyrB moieties resulting in crosslinking of the polymers to a hydrogel10,15. Finally, the dissolution of this
biohybrid material was achieved in a stimulus-inducible manner by the addition of novobiocin.
In this study we developed a novel strategy to reduce repetitive hepatitis B vaccine injections by the release of
the vaccine from a body depot in response to an orally available stimulus. To this aim, we incorporated a
commercially available hepatitis B vaccine (Engerix-B16) into a PEG-based biohybrid hydrogel depot being
responsive to the clinically licensed molecule novobiocin. Upon implantation into mice, the depot was dissolved
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at the scheduled point in time by the oral administration of the
stimulus thereby triggering the release of the vaccine. The elicited
immune response was comparable to conventional repetitive vaccine
injections. This orally controlled vaccination regime holds high pro-
mises for the simplification of hepatitis B vaccine delivery by redu-
cing the repetitive medical consultations thereby solving a major
obstacle in increasing hepatitis B vaccination coverage.
Results
PEG-based pharmacologically tunable vaccine depot. As material
for the storage and the inducible release of the commercial hepatitis B
vaccine Engerix-B, we synthesized a polyethylene glycol (PEG)-
based hydrogel which incorporates the GyrB-aminocoumarin
switch15 rendering the material stimulus-responsive (Fig. 1). To
this aim, branched PEG molecules were covalently decorated with
the N-terminal subunit of the protein Gyrase B (GyrB). Addition
of the aminocoumarin antibiotic coumermycin leads to the
dimerization of the GyrB moieties resulting in hydrogel formation.
Due to its large size (from 100 nm up to 10 mm17), the vaccine can
physically be incorporated into the hydrogel network structure.
Addition of the inducing stimulus novobiocin competitively
replaces coumermycin from the GyrB protein resulting in hydrogel
dissolution and the release of the incorporated vaccine.
The GyrB protein was expressed in E. coli with a C-terminal hex-
ahistidine tag for purification and a cysteine for the coupling to the
PEG (GyrB-Cys). In order to further stabilize the hydrogel by addi-
tional crosslinks, a GyrB variant harboring an N- and C-terminal
cysteine was produced (Cys-GyrB-Cys). For the formation of the
hydrogel, the GyrB proteins were mixed with coumermycin at a
molar ratio of 251 followed by the coupling via its cysteines to vinyl-
sulfone-modified 8-arm PEG (PEG-VS, molar ratio of GyrB to VS
groups of 151) by a Michael-type addition mechanism. Initial tests
with different molar ratios of the cysteine-modified protein variants
revealed high inducibility of the hydrogel with amolar ratio of GyrB-
Cys to Cys-GyrB-Cys of 451 (Supplementary Fig. 1). This resulted in
a typical hydrogel composition of 401 mg (16 nmol) GyrB-Cys,
101 mg (4 nmol) Cys-GyrB-Cys, 11.1 mg (10 nmol) coumermycin
and 93.8 mg (20 nmol VS groups) PEG-VS in a hydrogel volume
of 5 ml. The chemical structure of the synthesized hydrogel was fur-
ther analyzed by NMR thereby confirming the quantitative reaction
of the polymer with the protein (Supplementary Fig. 2).
Having developed the hydrogel depot prototype, we evaluated its
potential to function as hepatitis B vaccine depot. To this aim,
commercially available hepatitis B vaccine (Engerix-B, GlaxoSmith-
Kline16) being composed of recombinantly expressed hepatitis B sur-
face antigen (HBsAg) particles adsorbed to metalhydroxide particles
(alum) were added to the synthesis during hydrogel formation lead-
ing to 1 mg HBsAg content per 5 ml hydrogel. Transfer of the formed
hydrogel depots to PBS resulted in 25% volumetric swelling
(Supplementary Fig. 3). During this period, only marginal amounts
of vaccine were released summing up to 4.8 (65) ng released vaccine
after 1 week.
The viscoelastic properties of the hydrogel vaccine depot were
analyzed by small-strain oscillatory shear rheometry in a frequency
range of 0.1 to 1 Hz resulting in storage moduli (G9) largely exceed-
ing the loss moduli (G0) (Fig. 2a). These typical values for a viscoe-
lastic polymer network are in congruence with published data15 and
demonstrate that the vaccine components do not negatively affect
the mechanical properties of the hydrogel.
Hydrogel vaccine release characteristics. For an application as
vaccine depot in vivo, the material needs to be sensitive to its
inducer under physiological conditions leading to the dissolution
of the hydrogel and the release of the incorporated vaccine load.
We tested these aspects in vitro by the incubation of vaccine-
loaded hydrogels in PBS containing 100 mM novobiocin and
monitoring the dissolution and release of the hydrogel protein
components by Bradford assay (Fig. 2b). Whereas hydrogels
incubated in the absence of novobiocin only showed a marginal
release of hydrogel components reaching a plateau level of 5%
dissolution after 8 h, addition of 100 mM novobiocin led to the
rapid and complete dissolution of the hydrogel within 2 h.
Simultaneously to the dissolution of the hydrogel, the incorporated
vaccine was also released with similar kinetics in the presence of
novobiocin whereas the absence of the inducer led to no detectable
vaccine release as determined by the quantification of the HBsAg
content in the supernatant (Fig. 2c).
In order to test the hydrogel’s suitability for the release of vaccines
in the body, we simulated the body distribution kinetics of
orally administered novobiocin by novobiocin pulse experiments
(Fig. 2d). Whereas no release of vaccine was detected with pulses
up to 10 min and partial release was observed with 20 min pulses of
100 mMnovobiocin, complete dissolution of the depot and release of
the vaccine was achieved when novobiocin was present for 1 h. This
confirms the suitability of the depot for applications in vivo as such a
pulse profile necessary for the response time of the depot can be
achieved in mice18,19 as well as in humans20,21 without affecting bio-
compatibility.
In order to test the depot for the longtime storage and release of
vaccines in the body, we incubated vaccine-loaded hydrogels at 4uC
and 37uC in synthetic body fluid (SBF22) emulating the ionic com-
position of extracellular body fluids. After 1 week, the hydrogels
stored at both temperatures still retained their responsiveness as
tested by the incubation in the presence of 100 mM novobiocin
(Fig. 2e) thereby releasing equal amounts of vaccine as compared
to fresh hydrogel depots (Fig. 2c).
Pharmacologically scheduled vaccination in mice. Encouraged by
the positive in vitro results regarding the suitability of the PEG-based
hydrogel as a vaccine depot, we evaluated its application as a depot
for the stimulus-inducible hepatitis B vaccine release for
immunization in mice (Fig. 3). This strategy would allow replacing
the boost injection of the vaccine by the simple oral administration of
the stimulus molecule thereby drastically reducing the need for
repetitive medical consultations. To this aim, we vaccinated mice
with a prime vaccine dose of the hepatitis B surface antigen
(HBsAg) vaccine (0.5 mg HBsAg per mouse) and co-administered
a vaccine-loaded hydrogel (releasing 0.5 mg HBsAg as quantified in
Figure 1 | Design of the drug-responsive hydrogel vaccine depot. A
molecular switch based on the interaction of the protein Gyrase B (GyrB)
to the aminocoumarin antibiotics coumermycin and novobiocin is
providing the responsiveness to the hydrogel. To this aim, 8-arm
polyethylene glycol (PEG) was end-functionalized with GyrB. Addition of
coumermycin dimerized GyrB thereby leading to hydrogel formation and
physical entrapment of the vaccine. Addition of novobiocin competitively
replaced coumermycin resulting in GyrB monomerization and hydrogel
dissolution and the release of the vaccine.
www.nature.com/scientificreports
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Figure 2 | Hydrogel vaccine depot characterization. (a) Viscoelastic properties of the hydrogel vaccine depot. Hydrogel discs of 40 ml harboring the
hepatitis B vaccine were prepared and pre-swollen in PBS for 1 h. The storage and lossmoduli G9 andG0were determined by small-strain shear rheometry
at frequencies from 0.1 to 1 Hz. (b) Novobiocin-inducible hydrogel dissolution. Hydrogels (5 ml) harboring the commercial hepatitis B vaccine (Engerix-
B) were incubated in PBS in the absence or presence of 100 mM novobiocin. Hydrogel dissolution was monitored by the quantification of the released
hydrogel protein components into the supernatant. Error bars represent the standard deviation of 6 replicas. (c) Novobiocin-inducible vaccine release.
5 ml hydrogels harboring the hepatitis B vaccine (0.2 mg/ml HBsAg content) were incubated in PBS optionally containing 100 mMnovobiocin. The release
of the vaccine from the hydrogels was followed by the quantification of the HBsAg content in the supernatant. Error bars represent the standard deviation
of 4 replicas. (d)Novobiocin pulse-dependent vaccine release. 5 ml hydrogels harboring the hepatitis B vaccine (0.2 mg/ml HBsAg content) were incubated
in PBS containing 100 mM novobiocin for the indicated time of the pulse followed by washing and further transfer to fresh PBS for 4 h. For samples
without novobiocin pulse (no), hydrogel depots were incubated in PBS for 1 h prior to transfer to fresh PBS for 4 h. The release of the vaccine from the
hydrogels was analyzed by the quantification of the total HBsAg content in the supernatant and expressed in % of the total continuous release from (c).
Error bars represent the standard deviation of 4 replicas. (e) Long-term functionality of the hydrogel vaccine depot. 5 ml hydrogels containing the
hepatitis B vaccine (0.2 mg/ml HBsAg content) were incubated in synthetic body fluid (SBF) at 4uC and 37uC for 1 week. Afterwards, hydrogels were
transferred to fresh SBF supplemented with 100 mM (1) or without (2) novobiocin. The release of the vaccine from the hydrogel was monitored by the
quantification of the HBsAg content in the supernatant. Error bars represent the standard deviation of 3 replicas.
www.nature.com/scientificreports
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Fig. 2b) subcutaneously on day 1. In order to dissolve the hydrogel
depot and release the boost vaccine dose, we orally administered the
stimulus molecule novobiocin on day 6, 7 and 8 (group 1, Fig. 3a).
For the stability evaluation of the vaccine depot in the body, we kept a
group of vaccine depot-harboring mice without administration of
novobiocin. For comparison to the classical immunization regime,
we injected to mouse groups the prime and boost vaccine doses on
day 1 and 7 or only a prime dose on day 1 (0.5 mg per dose, groups 3
and 4, respectively, Fig. 3a). After 98 days, the protective immune
response was determined by the quantification of theHBsAg-specific
antibody titer (anti-HBs, Fig. 3a). The mice harboring a vaccine
depot and having received the novobiocin stimulus (group 1)
showed significantly higher anti-HBs titers as compared to mice
not having received novobiocin (group 2) thereby demonstrating
that the vaccine is released from the depot in a stimulus-inducible
manner. Comparison of the hydrogel-mediated (group 1) to the
classical 2-dose injection regime (group 3) showed similar anti-
HBs titer levels demonstrating the efficacy of the novel depot-
based immunization. Additionally, mice not supplemented with
the stimulus novobiocin (group 2) retained the vaccine efficiently
in their hydrogel depot resulting in anti-HBs titers comparable to the
mice having only received a single prime vaccine dose (group 4).
In addition to the determination of anti-HBs titers, we character-
ized the ability of the sera to inhibit HBV infection in a cell-based
neutralization assay (Fig. 3b,c). To this aim, we pooled the sera of 4
mice of each respective group showing an anti-HBs titer around the
median (highlighted in black in Fig. 3a). For the neutralization
Figure 3 | Time-scheduled hydrogel-mediated hepatitis B vaccination in
mice. (a) Remote-controlled vaccination with hydrogels. A prime vaccine
dose (0.5 mg HBsAg) was administered to all mice on day 1. A hydrogel of
50 ml harboring 0.5 mg HBsAg vaccine was subcutaneously administered
to the mice of groups 1 and 2 on day 1. Oral doses of novobiocin were
administered to mice of group 1 twice on day 6 (15 and 11.25 mg per
mouse) and once on day 7 and 8 (15 mg per mouse). The boost vaccine
dose (0.5 mg HBsAg) was administered to group 3 on day 7. At day 98,
serum was withdrawn and HBsAg-specific antibody titers (anti-HBs) were
Figure 4 | Macroscopic characterization of the vaccine hydrogel depot.
Mice of group 1 and 2 (see Fig. 3a) were sacrificed at day 98 and the site of
gel administration was analyzed. The remaining non-dissolved hydrogel of
the mouse of group 2 is indicated by an arrow.
determined. The median of the anti-HBs titers is shown. Sera used for the
neutralization experiments are highlighted in black. (b) Hepatitis B virus
(HBV) neutralization activity of mouse sera. The sera of 4 mice with an
anti-HBs titer around the median of each group from (a) were pooled and
pre-incubated (in triplicates) with HBV followed by infection of HepaRG
cells and further incubation. Onday 12 post-infection (p.i.), the percentage
of positive cells for the HBV core antigen (HBcAg) was determined by
HBcAg-specific immune fluorescence staining in comparison to the total
cell number (DAPI stain). As an uncompeted control, HBV pre-incubated
without sera (HBV) and as a positive control, HBV pre-incubated with a
neutralizing antibody (MA 18/7) was used. (c) Quantification of secreted
viral markers. The amount of HBsAg and HBeAg (hepatitis B e antigen)
secreted from day 8 to 12 p.i. during the neutralization experiment in
(b) was determined by ELISA. The values are given as percentage of the
uncompeted (uncomp.) infection. Values of Secreted HBsAg were
analyzed for statistical significance. The sensitivity of the ELISA (cutoff) is
0.25% for HBsAg and 0.5% for HBeAg, respectively. Error bars represent
the standard error of the mean. * indicates differences in the median
at a level of significance with p , 0.05; ** corresponds to p , 0.01
and *** to p , 0.001.
www.nature.com/scientificreports
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experiment, the pooled sera were pre-incubated with a HBV
inoculum and subsequently tested for their infectivity to differen-
tiated HepaRG cells23. The extent of HBV neutralization was deter-
mined by the amount of HepaRG cells positive for the hepatitis B
core antigen (HBcAg) (Fig. 3b) as well as by the quantification of the
cell-secreted viral antigens HBsAg and hepatitis B e antigen (HBeAg)
(Fig. 3c). The hydrogel-mediated (group 1) and the classical (group
3) 2-dose regime showed high neutralization efficacy resulting in low
amounts of HBcAg positive cells and secretedHBsAg/HBeAg similar
to the pre-S1 specific HBV neutralizing antibody MA 18/724,25. On
the other hand, the sera of mice non-fed with novobiocin (group 2)
only showed a rudimentary protective effect being comparable to the
mice only having received a single vaccine dose (group 4). These
observations are in line with the levels of anti-HBs titers and further
underline comparable efficacy of the hydrogel-mediated and the
classical injection regime.
The promising immunological results were also reflected by the
macroscopic analysis of the hydrogel depot ofmice sacrificed after 98
days (Fig. 4). Whereas inspection of the vaccine depot administra-
tion site of the mice lacking novobiocin treatment showed an intact
tissue-surrounded hydrogel (arrow), no subcutaneous remnants of
the hydrogel were observed in mice treated with novobiocin.
Discussion
In this study, we presented a novel depot-based strategy for the on-
command scheduled delivery of a hepatitis B vaccine in mice. With
the developed hydrogel depot being sensitive to the pharmaceutical
substance novobiocin, the repetitive delivery of a vaccine could be
drastically simplified by the simple oral intake of a tablet containing
the stimulusmolecule. In contrast to other innovative polymer-based
vaccination methods26,27 and remote-controlled delivery strategies
such as implanted microchips which have recently been shown to
deliver therapeutic proteins in a pulse-like fashion in human28,
our system based on an orally available stimulus allows for simple
handling and therefore represents a highly attractive alternative for
the simplification of vaccination regimes especially in developing
countries. This hydrogel depot may further be suitable for the
externally controlled delivery of numerous other vaccines and
biopharmaceuticals.
Methods
Protein production. The vector pRG053 for the bacterial expression of Cys-GyrB-
Cys under the control of the phage T7 promoter was constructed by the amplification
of the 59-part of the gyrB gene from chromosomal E. coli K12 DNA using
oligonucleotides ORG033 (59-gtatcacatatgtgctcgaattcttatgactcctccag-39) and
OWW985 (59-ccagttacaagctttcagcaatggtgatggtgatgatggccttcatagtggaagtggtcttc-39)
and cloning the PCR product NdeI/HindIII into pWW30129.
The vectors pRG053 and pWW116615 for the expression of Cys-GyrB-Cys and
GyrB-Cys were transformed into E. coli BL21 STARTM (DE3) (Life Technologies,
Carlsbad, CA, cat. no. C601003). Protein production was induced in LB medium at
OD600 5 0.8 with 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) for 4 h at
37uC. The cells were pelleted (6000 3 g, 7 min, 4uC), resuspended in lysis buffer
(40 ml per 1000 ml initial culture volume, 50 mMNaH2PO4, 300 mMNaCl, 10 mM
imidazole, pH 8.0) and disrupted using a French press (1000 bar, 3 passages, APV,
DK, Albertslund, APV-2000). Cell debris was eliminated (30,000 3 g, 30 min, 4uC)
and the lysate was loaded onto a gravity flow Ni21-NTA-agarose Superflow column
(10 ml lysate per ml Ni21-NTA-agarose bead volume, Qiagen, Hilden, Germany, cat.
no. 30210) followed washing with 10 column volumes lysis buffer, 10 column
volumes wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0)
and elution with 2 column volumes elution buffer (50 mMNaH2PO4, 300 mMNaCl,
250 mM imidazole, pH 8.0). To the eluate, 10 mM ethylenediaminetetraacetic acid
sodium salt, pH 8 (EDTA)was added and stored at280uC. Protein concentrationwas
determined by the Bradford method (Bio-Rad, Hercules, CA, cat. no. 500-0006) with
bovine serum albumin (BSA, Sigma Aldrich, St. Louis, MO, cat. no. 05479) as
standard.
Hydrogel synthesis.The proteins Cys-GyrB-Cys andGyrB-Cys were concentrated to
100 mg/ml by ultrafiltration (10 kDa MWCO, Corning, Lowell, MA, cat. no.
431483), a 20-fold molar excess of TCEP (Tris(2-carboxyethyl)phosphine
hydrochloride, Sigma Aldrich, cat. no. C4706, 33 mg/ml in 500 mMNaHCO3 buffer
pH 9) was added and incubated at room temperature for 1 h. The buffer of the
reduced proteins was exchanged to reaction buffer (2.68 mM KCl, 1.47 mM
KH2PO4, 8.03 mM Na2HPO4, 137 mM NaCl, 2 mM EDTA pH 8) on a desalting
column (Thermo Fisher Scientific,Waltham,MA, cat. no. 43233) and the protein was
concentrated to 200 mg/ml by ultrafiltration under nitrogen atmosphere.
Typical 5 ml hydrogels were prepared by mixing the proteins GyrB-Cys (401 mg,
16 nmol) and Cys-GyrB-Cys (101 mg, 4 nmol) in a molar ratio of 451 (unless
indicated otherwise) to a total amount of 20 nmol protein in 4 ml reaction buffer
followed by the addition of coumermycin (Promega, Madison, WI, cat. no. C9451,
50 mg/ml in DMSO) in amolar ratio of GyrB:coumermycin 5 251 and incubation at
room temperature for 1 h. Hydrogel formation was started by the addition of 0.15 ml
of 3.3 M triethanolamine and 93.8 mg (20 nmolVS groups) 8-arm polyethylenglycol-
vinylsulfone (PEG-VS, derived from a previous study15). Hydrogel formation was
completed by incubation at 25uC in a humidified atmosphere for 24 h.
For the production of vaccine-loaded hydrogels, commercially available hepatitis B
vaccine (Engerix-B, GlaxoSmithKline, Mu¨nchen, Germany, cat. no. 7504643, 20 mg/
ml Alum-adsorbed HBsAg) was concentrated to 0.4 mg/ml by centrifugation (13,000
3 g, 1 min). For hydrogel formation, 0.2 mg/ml (final hydrogel volume) of concen-
trated HBsAg vaccine was added to the hydrogel prior to the addition of triethano-
lamine and PEG-VS.
Mechanical hydrogel characterization. For rheological analysis, vaccine-loaded
hydrogel discs of 40 ml volume were prepared between two siliconized glass slides
(1 mm height) and pre-swollen in PBS (2.68 mM KCl, 1.47 mM KH2PO4, 8.03 mM
Na2HPO4, 137 mM NaCl, pH 7.4) for 1 h. The storage and loss moduli (G9 and G0)
were determined by small strain oscillatory shear experiments on amodular advanced
rheometry system II (MARS, Thermo Fisher Scientific) with parallel steel plates
(20 mm) at 20uC. Hydrogels were placed between the plates and the gap was adjusted
to 0.5 mm. Frequency-sweep experiments were performed at constant strain (20%)
from 0.1 to 1 Hz.
Hydrogel characterization. For hydrogel dissolution kinetics, 5 ml vaccine-loaded
hydrogels were pre-swollen in PBS for 24 h. Afterwards, theywere transferred to 1 ml
PBS containing the indicated novobiocin concentrations. The stimulus-responsive
dissolution of the hydrogel was monitored by the quantification of the released
protein components in the supernatant by the Bradford method. Released hepatitis B
vaccine was quantified by ELISA (Enzygnost HBsAg 6.0, Siemens, Mu¨nchen,
Germany, cat. no. OPFM03) using fresh hepatitis B vaccine as a standard.
For novobiocin pulse-dependent vaccine release experiments, 5 ml vaccine-loaded
hydrogels were pre-swollen in PBS for 24 h. Afterwards, they were incubated in 1 ml
PBS containing 100 mMnovobiocin for the corresponding time of the pulse followed
by washing steps (4 3 2 min in 1 ml PBS) and further incubation in 1 ml fresh PBS
for 4 h. For samples without novobiocin pulse, hydrogel depots were incubated in
PBS for 1 h prior to washing and transfer to fresh PBS for 4 h. Total released hepatitis
B vaccine was quantified by ELISA as mentioned above.
For long-term functionality tests, 5 ml vaccine-loaded hydrogels were transferred
to 1 ml synthetic body fluid (SBF22) supplemented with gentamycin (40 mg/ml) and
puromycin (10 mg/ml) and incubated for 1 week at 4uC and 37uC, respectively.
Afterwards, hydrogels were transferred to fresh SBF containing the indicated novo-
biocin concentrations and the released hepatitis B vaccine was quantified by ELISA as
mentioned above.
Mouse experiments. For vaccination studies, female Swiss CD 1 mice (Janvier SAS
CS 4105, Le Genest St Isle F-53941 St Berthevin, France) were used. A minimum
amount of 7 mice was kept for each group. For standard vaccination, the commercial
Engerix-B vaccine was diluted to 5 mg/ml in PBS and injected (100 ml per mouse).
50 ml hydrogels containing 0.2 mg/ml vaccine were applied subcutaneously on the
back of the mice under sodium pentobarbital (Nembutal) 6% anesthesia, 45 mg/kg.
Novobiocin was administered by gastric tube (75 mg/ml in 150 mMNaCl) in 2 doses
(600 and 350 mg/kg) on day 6 and in 1 dose (600 mg/kg) on day 7 and 8. Serum
samples were withdrawn on day 98. All animal experiments were performed
according to the directives of the European Community Council (86/609/EEC),
approved by the French Republic (no. 69266310), and performed by M.D.E. and
G.C.E. at Lyon University.
Quantification of serum antibody levels. For the determination of total antibody to
Hepatitis B surface antigen (anti-HBs), the mouse serum was analyzed using a
sandwich immunoassay (ADVIA Centaur aHBs II, Siemens Healthcare Diagnostics,
Eschborn, Germany) on an ADVIA Centaur XP system. Antibody titers were
quantified in mIU/ml.
Neutralization experiments. Neutralization assays were performed as recently
described23. Briefly, HepaRG cells were grown inWilliams’ medium E supplemented
with 10% heat-inactivated fetal calf serum, 50 U penicillin/ml, 50 mg streptomycin/
ml, 5 mg insulin/ml, and 50 mM hydrocortisone hemisuccinate. The cells were split
every 2 weeks at a ratio of 155. Fourteen days before infection, cell differentiation was
induced by adding 1.5% DMSO to the maintenance medium30. The medium was
exchanged every 3 days.
HBV was produced in HepAd38 cells31 grown on 5-stack cell factories (Corning,
cat. no. 3319). 450 ml supernatants were collected every third day and subjected to
automated heparin affinity chromatography on 5 ml HiTrap Heparin columns (GE
Healthcare, Piscataway, NJ, cat. no. 17-0407-01). Bound virions were eluted with a
linear NaCl gradient. Immediately after elution, the virus peak fractions
(340 1/2 100 mM NaCl, 20 mM TrisCl, pH 7.4) were rebuffered to physiological
www.nature.com/scientificreports
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salt concentrations (140 mMNaCl) by addition of H2O and supplemented with FCS
to a final concentration of 5%. Aliquots were stored at 280uC.
For HBV infection, differentiated HepaRG cells (5 3 105 cells/well of a 24-well
plate) were incubated with a 33-fold dilution of the concentrated HBV stock in
medium in presence of 4% polyethylene glycol 8000 for 16 h at 37uC. For neutral-
ization of HBV viral particles, the sera of 4 mice of each group with an antibody titer
around the median (Fig. 3a) were pooled and pre-incubated with the HBV inoculum
(3 ml serum were added per 7.5 ml diluted inoculum) for 30 min at 37uC, followed by
co-incubation with the cells for 16 h at 37uC as described in23. Pooled sera frommice
taken before vaccination used in same volumes served as serum controls. The
humanized monoclonal antibody MA 18/7 (derived from Humabs, Bellinzona,
Switzerland), directed against the pre-S1 domain of the largeHBs protein24,25 was used
as a positive control (1 mg/ml). At the end of the incubation, the cells were washed
three times and further cultivated. Medium was exchanged every 2 to 4 days. To
guarantee the best compatibility between the different serum pools, the respective test
was performed in 24-well plates with the same batch of cells. The amounts of hepatitis
B surface antigen (HBsAg) and the hepatitis B e antigen (HBeAg) secreted into the
supernatant from day 8 to 12 post-infection (p.i.) were determined by immunoassays
(ARCHITECT HBsAg, Abbott Laboratories, Wiesbaden, Germany and ADVIA
Centaur HBeAg, Siemens).
The HBV core antigen (HBcAg) as an additional virological marker was analyzed
at day 12 p.i. by HBcAg-specific immunofluorescence as described in23. Analysis of
images was performedwith ImageJ software using the nucleus counter function of the
Wright Cell Imaging Facility (WCIF) plug-in to count the number of labeled nuclei
(DAPI) and HBcAg-positive cells. For each serum pool, 10 images per well were
analyzed.
Statistical analysis. Statistical comparison among groupswas performed using a two-
tailed unpaired t-test. p values # 0.05 were considered statistically significant.
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